Stoke Therapeutics (STOK) Total Liabilities (2018 - 2026)

Stoke Therapeutics' Total Liabilities history runs 9 years deep, the most recent figure standing at $48.4 million for Q1 2026.

• In Q1 2026, Total Liabilities fell 14.81% year-over-year to $48.4 million; the TTM figure through Mar 2026 stood at $48.4 million (down 14.81% YoY), while the FY2025 annual figure was $66.0 million, up 55.12% from the prior year.
• Total Liabilities was $48.4 million for Q1 2026 at Stoke Therapeutics, down from $66.0 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $77.1 million in Q2 2022 to a low of $42.5 million in Q4 2024.
• Historically, Total Liabilities has averaged $63.2 million across 5 years, with a median of $66.0 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Total Liabilities soared 351.98% in 2022, then slumped 38.16% in 2024.
• A 5-year view of Total Liabilities shows it stood at $71.2 million in 2022, then declined by 3.43% to $68.8 million in 2023, then tumbled by 38.16% to $42.5 million in 2024, then jumped by 55.12% to $66.0 million in 2025, then slipped by 26.64% to $48.4 million in 2026.
• The last three Total Liabilities figures came in at $48.4 million (Q1 2026), $66.0 million (Q4 2025), and $52.2 million (Q3 2025), per Business Quant data.